CAR-T therapy aimed at tough kidney disease in kids — but trial never started

NCT ID NCT06842589

Terminated Disease control Sponsor: The Children's Hospital of Zhejiang University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This was a planned early-stage trial to test whether anti-CD19 CAR-T cells could safely help children with multi-drug resistant nephrotic syndrome, a serious kidney condition. The study was withdrawn before any patients were enrolled, so no data on safety or effectiveness were collected. The approach aimed to use engineered immune cells to target and possibly calm the overactive immune system driving the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anti-CD19 CAR-T cells
What this could lead to: If this approach had been tested and worked, it could point toward a new treatment option for children with hard-to-treat nephrotic syndrome.
What could go wrong: This trial was withdrawn before enrolling any participants, so no results are available. CAR-T therapy carries serious risks like cytokine release syndrome and infections, and its use in kidney disease is very early and uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CAR-T CELL THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic multidrug-resistant nephrotic syndrome nephrotic syndrome steroid-resistant nephrotic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CAR-T CELL THERAPY MULTI-DRUG RESISTANT NEPHROTIC SYNDROME

More trials for these conditions

Other studies related to the condition(s) this trial covers.